March 22, 2016 1:10pm
Learn who is stumbling and what the mumbling means ...
RMi is the only source of actionable intelligence for the stem, cell and gene therapy and regenerative medicine’s universe (SCGT&RM).
For 6 years, you’ve had complimentary access to unbiased analysis, in-depth analytics, and informational synthesis along with RMi’s exclusive listing of “our” universe’s stocks and their potential for gains and losses.
But exclusivity is now here ...
Starting April 1, 2016 access to RegMed Investors’ targeted content will be by subscription only. As an appreciation to my most valued readers, I am offering 20% off the full subscription price for one full year of RegMed Investors - a $200 savings.
For continued access to what one industry CEO calls the “Bible” for smart investing in the SCGT&RM sector, click on the button below: